Effects of a probiotic fermented milk on functional constipation: A randomized, double-blind, placebo-controlled study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 7, 2013, Pages 1141-1147

  Mazlyn, Mena Mustapha ^a   Nagarajah, Lee Hun Leong ^d   Fatimah, Arshad ^a   Norimah, A Karim ^b   Goh, Khean Lee ^c  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d Vinayaka Missions International University College   (Malaysia)

Author keywords

Constipation; Lactobacillus casei; Probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABNORMAL FECES COMPOSITION; ADULT; ARTICLE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DEFECATION DISORDER; DEFECATION HABIT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FERMENTED MILK; FERMENTED PRODUCT; HARD FECES; HUMAN; LACTOBACILLUS CASEI; MAJOR CLINICAL STUDY; MALE; MILK; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SUPPLEMENTATION;

EID: 84879447928     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12168     Document Type: Article

References (30)

1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am. J. Gastroenterol. 2011; 106: 1582-1591; quiz 1581, 1592.
2. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II: The Functional Gastrointestinal Disorders, 2nd edn. McLean, VA: Degnon Associates, 2000.
3. Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment. Pharmacol. Ther. 2010; 31: 938-949.
4. Pohl D, Tutuian R, Fried M. Pharmacologic treatment of constipation: what is new? Curr. Opin. Pharmacol. 2008; 8: 724-728.
5. Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the evaluation of probiotics in food: Report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. 2002.
6. Adams MR, Marteau P. On the safety of lactic acid bacteria from food. Int. J. Food Microbiol. 1995; 27: 263-264.
7. Heimbach JT. Generally recognized as Safe (GRAS) determination for the use of Lactobacillus casei strain Shirota as a food ingredient. 2012. Cited 10 Aug 2012. Available from URL: http://www.accessdata.fda.gov/scripts/fcn/gras_notices/GRN000429.pdf
8. Agrawal A, Houghton LA, Morris J etal. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 2009; 29: 104-114.
9. Yang YX, He M, Hu G etal. Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J. Gastroenterol. 2008; 14: 6237-6243.
10. Higashikawa F, Noda M, Awaya T, Nomura K, Oku H, Sugiyama M. Improvement of constipation and liver function by plant-derived lactic acid bacteria: a double-blind, randomized trial. Nutrition 2010; 26: 367-374.
11. Chmielewska A, Szajewska H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J. Gastroenterol. 2010; 16: 69-75.
12. Quigley EM. The enteric microbiota in the pathogenesis and management of constipation. Best Pract. Res. Clin. Gastroenterol. 2011; 25: 119-126.
13. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can. J. Gastroenterol. 2003; 17: 655-659.
14. Sakai T, Makino H, Ishikawa E, Oishi K, Kushiro A. Fermented milk containing Lactobacillus casei strain Shirota reduces incidence of hard or lumpy stools in healthy population. Int. J. Food Sci. Nutr. 2011; 62: 423-430.
15. Matsumoto K, Takada T, Shimizu K etal. The effects of a probiotic milk product containing Lactobacillus casei strain Shirota on the defecation frequency and the intestinal microflora of sub-optimal health state volunteers: a randomized placebo-controlled cross-over study. Biosci. Microflora 2006; 25: 39-48.
16. Drossman DA, Dumitrascu DL. Rome III: new standard for functional gastrointestinal disorders. J. Gastrointestin. Liver Dis. 2006; 15: 237-241.
17. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491.
18. Kwan AC, Bao TN, Chakkaphak S etal. Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample. J. Gastroenterol. Hepatol. 2003; 18: 796-802.
19. Chan AO, Lam KF, Hui WM etal. Validated questionnaire on diagnosis and symptom severity for functional constipation in the Chinese population. Aliment. Pharmacol. Ther. 2005; 22: 483-488.
20. Karlsson J, Engebretsen L, Dainty K, ISAKOS Scientific Committee. Considerations on sample size and power calculations in randomized clinical trials. Arthroscopy 2003; 19: 997-999.
21. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33: 818-824.
22. Yen CH, Tseng YH, Kuo YW, Lee MC, Chen HL. Long-term supplementation of isomalto-oligosaccharides improved colonic microflora profile, bowel function, and blood cholesterol levels in constipated elderly people-a placebo-controlled, diet-controlled trial. Nutrition 2011; 27: 445-450.
23. Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am. J. Gastroenterol. 2011; 106: 120-129.
24. Lembo AJ, Schneier HA, Shiff SJ etal. Two randomized trials of linaclotide for chronic constipation. N. Engl. J. Med. 2011; 365: 527-536.
25. Food and Drug Administration, United States. Guidance for Industry: Irritable Bowel Syndrome-Clinical Evaluation of Products for Treatment. May 2012. Cited 18 Jul 2012. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM205269.pdf
26. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 (Suppl. 2): II69-77.
27. Musial F, Klosterhalfen S, Enck P. Placebo responses in patients with gastrointestinal disorders. World J. Gastroenterol. 2007; 13: 3425-3429.
28. De Filippo C, Cavalieri D, Di Paola M etal. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. U. S. A. 2010; 107: 14691-14696.
29. McCrea GL, Miaskowski C, Stotts NA, Macera L, Hart SA, Varma MG. Review article: self-report measures to evaluate constipation. Aliment. Pharmacol. Ther. 2008; 27: 638-648.
30. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr. Psychometric validation of a constipation symptom assessment questionnaire. Scand. J. Gastroenterol. 1999; 34: 870-877.